Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Apr 9;8(4):e996.
doi: 10.1212/NXI.0000000000000996. Print 2021 Jul.

Cytomegalovirus Encephalitis Under Fingolimod Mimicking Progressive Multifocal Leukoencephalopathy?

Dierk Oel  1 , Kinga Rigler-Hohenwarter  1 , Johannes Trenkler  1 , Raffi Topakian  2
Affiliations
Case Reports

Cytomegalovirus Encephalitis Under Fingolimod Mimicking Progressive Multifocal Leukoencephalopathy?

Dierk Oel et al. Neurol Neuroimmunol Neuroinflamm. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Evolution of MRI Abnormalities Before and After Treatment With IV Ganciclovir
“Baseline” (T2 axial and fluid-attenuated inversion recovery [FLAIR] axial): MRI before starting fingolimod shows no substantial lesions in the left frontal and both occipital regions; “m13” (FLAIR space, axial and FLAIR space, sagittal): Routine MRI 13 months after starting fingolimod shows new (asymptomatic) bilateral occipital hyperintense lesions at the gray matter-white matter junction and one new left frontal lesion; “m24” (FLAIR space, sagittal): MRI 24 months after starting fingolimod shows progression of the right occipital lesion; “m26” (FLAIR space, sagittal): MRI 26 months after starting fingolimod shows further progression of the right occipital lesion; “m30” (FLAIR space, sagittal): MRI 30 months after starting fingolimod shows regression of the right occipital lesion after discontinuation of fingolimod and treatment with IV ganciclovir over 3 weeks.
See this image and copyright information in PMC

References

    1. Arvin AM, Wolinsky JS, Kappos L, et al. . Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72:31–39. - PMC - PubMed
    1. Berger JR, Cree BA, Greenberg B, et al. . Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2018;90:e1815–e1821. - PMC - PubMed
    1. Berger JR, Aksamit AJ, Clifford DB, et al. . PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80:1430–1438. - PMC - PubMed
    1. Nakamichi K, Inoue N, Shimokawa T, Kurane I, Lim CK, Saijo M. Detection of human herpesviruses in the cerebrospinal fluid from patients diagnosed with or suspected of having progressive multifocal leukoencephalopathy. BMC Neurol. 2013;13:200. - PMC - PubMed
    1. Holland NR, Power C, Mathews VP, Glass JD, Forman M, McArthur JC. Cytomegalovirus encephalitis in acquired immunodeficiency syndrome (AIDS). Neurology. 1994;44:507–514. - PubMed

Publication types

MeSH terms

Substances